Tesis Biosciences has introduced a new predictive genomic assay that will enable physicians to identify suitable drug therapies and dosages for patients across diseases and conditions.

The new pharmacogenomics test will help evaluate the drug metabolism of patients based on their genetic makeup to determine the effectiveness of the drug.

This approach is expected to improve the accuracy of drug therapy and minimise the number of adverse drug reactions while also reducing treatment costs.

Tesis Biosciences chief research officer Divyen Patel said: “It removes the guesswork from deciding which drugs, in which dosage, will be most effective for patients and allows for personalised drug therapies.

“Previously, the dosage has often been decided on criteria no more sophisticated than a patient’s height and weight, often with harmful results.”

The new test has the ability to predict how patients interact with several medications from various classifications, including drugs prescribed to treat common diseases such as diabetes, depression, high blood pressure, cancer and chronic pain.

Equipped with a proprietary software platform, the test uses millions of data points to compare a patient’s genetic profile to metabolise or clear particular drug types to make the best therapeutic choice.

The company has already obtained Clinical Laboratory Improvement Amendments certification for the test. It will file an application to receive formal approval for the test from the US Food and Drug Administration.

Patel added: “This test can save millions in healthcare costs by allowing providers to determine from the start which drugs to prescribe and in what dosage, thus avoiding unnecessary and ineffective treatments and medications.”